Streptomyces – The Industrious Antibiotic Producer

Like other actinomycetes, the Streptomyces group of microbes straddles the somewhat artificial boundary between bacteria and fungi. Growth on culture plates looks ‘fungal’ and the organism produces spores and germtubes that look like mycelia.  Nonetheless these soil organisms are bacteria and of great interest to microbiologists as the producers of many antibiotics Continue reading Streptomyces – The Industrious Antibiotic Producer

Brilacidin – QIDP Drug At a Critical Juncture

At around this time (July 2015), Cellceutix is expected to hammer out a Phase 3 program for brilacidin, its defensin-mimetic and host-defense protein (HDP) mimic structurally similar to magainin, with FDA. Brilacidin is certainly an interesting novel compound, coming from a new class, with a unique mode of action.  It has Continue reading Brilacidin – QIDP Drug At a Critical Juncture

Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path

Whenever a new drug is in late stage development, its prospects become the focus of intense scrutiny. Plazomicin (ACHN-490), like any Phase 3 drug should be evaluated along the following dimensions: Differentiation: within its class & compared to competitors: Does it have a unique clearly definable profile? Addressing an unmet need: Continue reading Plazomicin – A Quick Take On A Complex Drug With A Complex Development Path